EMBL -EBI: Virtual Event, Tuesday 10th November 2020

Background & Motivation
• Digital Endpoints/Biomarkers based on mobile devices and sensor technology are currently
being investigated in many clinical studies
• Data collected from sensors is entirely different from any other clinical data collected
• No agreement or guidance on how to best process and analyse sensor data exists
• First guidance proposals on how to develop digital endpoints/biomarkers for clinical studies
only just appearing

Scope
• Overview on current strategies to develop digital endpoints/biomarkers
• Overview on current practices in collecting, processing and analyzing digital biomarker data
• Use cases from both academia and industry
• Analysis related issues like statistical methods for high-dimensional time series data;
addressing data types like touch and voice; relationship to disease and established clinical
outcomes
• Data related issues like missing data, gathering, transferring, anonymizing, sharing

Anticipated workshop outcomes
• Shared understanding on current practices for digital biomarker data analysis in clinical
studies
• Understanding current gaps and future steps of digital biomarker data analysis

Click here for information and registration

Content courtesy of EMBL -EBI

Related Post

  • Posted on 4 September, 2024
    Dr. Adam Vogel, CSO of Redenlab, will be speaking alongside Dr. Tairmae Kangarloo, Associate Director of Digital Strategy at Takeda,...
    • Posted on 3 September, 2024
      Redenlab is proud to announce our participation in the 14th International Conference on Frontotemporal Dementias (ICFTD), to be held in...
      • Posted on 30 May, 2024
        Join Redenlab at the upcoming Huntington’s Disease Society of America (HDSA) National Convention, starting on the 30th of May 2024...